<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00051129</url>
  </required_header>
  <id_info>
    <org_study_id>C-02-27</org_study_id>
    <nct_id>NCT00051129</nct_id>
  </id_info>
  <brief_title>Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)</brief_title>
  <official_title>An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate anecortave acetate compared to placebo for
      maintenance of visual acuity after 24 months of treatment in patients with subfovial
      choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in logMAR visual acuity score at 12 months</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">291</enrollment>
  <condition>Macular Degeneration</condition>
  <condition>Maculopathy, Age-Related</condition>
  <condition>Age-Related Maculopathies</condition>
  <condition>Age-Related Maculopathy</condition>
  <condition>Maculopathies, Age-Related</condition>
  <arm_group>
    <arm_group_label>Anecortave Acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anecortave Acetate Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate 15 mg sterile suspension</intervention_name>
    <description>0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection</description>
    <arm_group_label>Anecortave Acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anecortave Acetate Vehicle</intervention_name>
    <description>Administered as a posterior juxtascleral injection</description>
    <arm_group_label>Anecortave Acetate Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the
             study eye.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Under 50 years.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2003</study_first_submitted>
  <study_first_submitted_qc>January 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2003</study_first_posted>
  <disposition_first_submitted>November 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 28, 2012</disposition_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>anecortave acetate</keyword>
  <keyword>wet AMD</keyword>
  <keyword>age-related macular degeneration</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Maculopathy, Age-Related</keyword>
  <keyword>Age-Related Maculopathies</keyword>
  <keyword>Age-Related Maculopathy</keyword>
  <keyword>Maculopathies, Age-Related</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anecortave</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

